News | News By Subject | News by Disease News By Date | Search News

Renal Cell Carcinoma News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Bionomics Limited Sinks As Renal Cancer Drug Fails Key Phase 2 Test     3/19/2014
FDA Committee Turns Down AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.)/Astellas Pharma Inc.'s Cancer Drug     5/6/2013
Pfizer Inc. Kidney Cancer Drug Fails as Initial Treatment     10/18/2012
Pfizer Inc.'s Torisel Drug Fails in a Combination Study     8/13/2012
Pfizer Inc.'s Torisel Fails Phase III Renal Cell Carcinoma Study in Showdown Against Bayer HealthCare's Nexavar     5/16/2012
Argos Therapeutics, Inc. Raises $25 Million Series D Financing     4/24/2012
AVEO Pharmaceuticals, Inc. Announces Publication of Positive Tivozanib Phase 2 Clinical Trial Results in Journal of Clinical Oncology     4/12/2012
FDA Approves Pfizer Inc.'s INLYTA® (axitinib) for Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)     1/30/2012
Pfizer Inc. Receives Backing for Late-stage Trial of Kidney Cancer Drug in Asia     1/9/2012
Pfizer Inc. Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)     11/19/2010
GlaxoSmithKline (JOBS) Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT(TM)     10/7/2009
Novartis AG Release: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib     3/31/2009
Oxford BioMedica PLC Announces Data Safety Monitoring Board Recommendation to Continue Phase 3 Study; Achievement Triggers €10 M Milestone Payment from Sanofi-Aventis (France)     2/20/2008
ImClone Systems Incorporated: Phase II Study of IMC-1121B for Advanced Renal Cell Cancer Opens for Patient Enrollment     8/24/2007
Genentech, Inc. Release: Interim Analysis Of Phase III Trial Shows Avastin Plus Interferon Therapy Improved Progression-Free Survival In Patients With Previously Untreated Advanced Renal Cell Carcinoma     12/12/2006

Featured Stories

More News
Enrollment In Argos Therapeutics, Inc. (ARGS)' Pivotal Phase 3 ADAPT Trial Of AGS-003 For Metastatic Renal Cell Carcinoma Surpasses Fifty Percent     9/18/2014
Cerulean Pharma Inc. (CERU) Announces CRLX101 Combination Data At 2014 American Society of Clinical Oncology Annual Meeting     6/3/2014
Argos Therapeutics, Inc. (ARGS) Release: Treatment With AGS-003 And Sunitinib Associated With Doubling Of Expected Survival In Patients With Unfavorable Risk Metastatic Renal Cell Carcinoma (mRCC)     6/2/2014
Prometheus Laboratories Inc. Release: PROCLAIM Patient Registry Data Show Extension Of Overall Survival Benefits Beyond Complete And Partial Responders In Metastatic Renal Cell Carcinoma Patients Treated With High-Dose Interleukin-2 (HD IL-2)     5/30/2014
Rexahn Pharmaceuticals, Inc. (RNN) Initiates Phase 2a Clinical Trial Of Archexin® In Patients With Metastatic Renal Cell Carcinoma     1/14/2014
Argos Therapeutics, Inc. Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates With Overall Survival Benefit in Patients With Metastatic Renal Cell Carcinoma     11/11/2013
Bionomics Limited (BMICY.PK) Completes Enrollment for BNC105 Phase II Renal Cancer Trial     6/11/2013
Active Biotech AB (BTPC)'s Project ANYARA Improved Overall Survival in a Subgroup of Renal Cell Cancer Patients     6/3/2013
Argos Therapeutics, Inc. Announces Updated Phase 2 Data for AGS-003 Personalized Immunotherapy for Metastatic Renal Cell Carcinoma     2/15/2013
Acceleron Pharma Initiates Phase 2 Study of Dalantercept (ACE-041) to Treat Patients With Metastatic Renal Cell Carcinoma     2/5/2013
Results From Active Biotech AB (BTPC)'s Phase II/III ANYARA Trial for the Treatment of Renal Cell Cancer     1/28/2013
Argos Therapeutics, Inc. Identifies Immune Response Marker Connected to Prolonged Overall Survival in mRCC Patients Treated With AGS-003     10/11/2012
AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) (AVEO) and Astellas Pharma Inc. (YPH.BE) Announce Submission of New Drug Application for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma     9/28/2012
Pfizer Inc. (PFE) Receives EU Marketing Authorization for INLYTA®(Axitinib)     9/4/2012
Seattle Genetics, Inc. (SGEN) Announces Initiation of a Phase Ib Trial of SGN-75 in Combination With Everolimus for Patients With Renal Cell Carcinoma     8/24/2012

//-->